Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution

Generic substitution of antiepileptic drugs: What's a clinician to do?

Generic substitution of antiepileptic drugs remains a controversial area without a clear consensus to guide clinicians. The US Food and Drug Administration (FDA) requires rigorous testing of generic products and states that all approved products are interchangeable. FDA studies involve single doses in normal subjects so may not represent the performance of generic products in people with epilep...

Intentional forgetting benefits from thought substitution.

This study provides both experimental and correlational evidence that forgetting in the think/no-think paradigm (Anderson & Green, 2001) is sensitive to the substitution of thoughts about new events for thoughts that are to be suppressed. All the participants learned a list of adjective-noun pairs. Then the adjectives were presented as cues for recalling half of the nouns and as cues for suppre...

Clarification regarding generic substitution for psychotropic drugs.

Generic substitution: issues for problematic drugs.

The methodology and criteria for bioequivalence testing have been firmly established by the Food and Drug Administration (FDA). For certain drugs with a narrow therapeutic index (e.g., digoxin, levothyroxine, warfarin), generic substitution may not be advisable or even allowable, depending on the substitution laws of individual states. Digoxin and levothyroxine tablets are examples of drugs for...

Antiepileptic drugs: the drawbacks of generic substitution.

The need to curb the rising costs of health care has led policy-makers in many countries to consider widespread generic substitution of brand-name drugs as an eff ective means to cut costs. For example, on January 5, 2010, the NHS in England began a 3-month consultation to seek views on plans to automatically substitute branded drugs with generic versions in primary care. However, doctors, pati...